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Abstract
Purpose In order to prevent postpartum hemorrhage in
caesarean section under spinal anesthesia, patients rou-
tinely receive oxytocin. In this study we compared the
efficacy of Methylergonovine and Oxytocin on hemody-
namic stability and bleeding amount in caesarean section.
Materials and methods In this randomised controlled trial
study, 80 patients candidate for elective caesarean section
under spinal anesthesia divided to two groups: 40 patients
in control group received oxytocin and 40 ones in case
group received methylergonovine.
Results There was no differences between groups in
Mean age, baseline hemodynamic values, after spinal
anesthesia and recovery (except diastolic blood pressure
min 20), time of uterine atony, dizziness; nausea and
vomiting. After drug administration (oxytocin and methy-
lergonovine), systolic blood pressure in minutes 1, 10, 15
and diastolic blood pressure in minutes 1, 3, 20 increased in
case group statistically more than control group. In control
group, heart rate in minutes 1, 5 increased significantly
more than the other group. Mean arterial blood pressure in
minutes 1, 3, 5, 10, 15 reduced significantly more than in
control group. Need to vasoconstrictor drug statistically
was less in case group (p \ 0.0001).
Conclusion Methylergonovine induced significantly
more hemodynamic stability. Adverse effects were similar
between two groups. We recommend the use of methy-
lergonovine in patients with caesarean section under spinal
anesthesia because of its hemodynamic stability and low
need to vasoconstrictor drugs.
Keywords Methylergonovine  Oxytocin  Hemodynamic 
Spinal anesthesia  Elective cesarean
Introduction
Today, Caesarean section is the most common surgery in
the United States [1], and both regional and general anes-
thesia are commonly used in these procedures [2].
The American College of Obstetrics and Gynecology
has concluded that regional anesthesia is the preferred
choice to control labor pain and should be used if no
contraindication is present [3]. Hypotension (systolic blood
pressure less than 90 mmHg) is seen in nearly 33 % of
patients under spinal anesthesia, and it is the most common
complication of spinal anesthesia for delivery [4].
Postpartum hemorrhage (PPH) is one of the four main
causes of maternal mortality due to delivery after 20 weeks
of gestational age (in addition to thromboembolism,
hypertensive disorders, and infection) [1]; it is probably the
most common one [1]. Uterine atony—inability of the
uterus to contract properly after delivery—is the most
prevalent cause of PPH [3]. The incidence of uterine atony
is on the increase in both vaginal delivery and cesarean
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section [5]. Oxytocin is still the first-line uterotonic drug
for prophylaxis and treatment of uterine atony [5]. A study
by Jonsson et al. [6] has shown that bolus dosage of oxy-
tocin induces transient hypotension and reflex tachycardia
and increases cardiac output in healthy women undergoing
elective caesarean section under spinal anesthesia; these
effects are dose-dependent. Moreover, systemic hemody-
namic changes or coronary vasospasm lead to myocardial
ischemia and electrocardiogram (ECG) changes [6]. The
effects of oxytocin are limited by the numbers and situation
of oxytocin receptors. It is worth mentioning that increas-
ing the dosage does not necessarily improve uterine con-
tractions if numbers and quality of the receptors are
inadequate [7]. Therefore, the other uterotonic agents, with
different mechanisms, could be used instead [7]. Methy-
lergonovine continues to be the second-line uterotonic
agent in the prophylaxis and treatment of PPH [5].
Methylergonovine is a synthetic alkaloid that causes strong
contractions of the myometrium; however, parenteral
administration of this alkaloid, especially via the intrave-
nous route, sometimes causes transient but severe elevated
blood pressure [3]. Some studies have shown that oxytocin
plus ergometrine is more effective than oxytocin alone in
the prevention of PPH [8–10].
The objective of this study was to compare the efficacy
of methylergonovine vs. oxytocin on hemodynamic sta-
bility and bleeding amount in cesarean section under spinal
anesthesia. The study also considered side effects and time
of atony.
Materials and methods
A prospective, randomized, single-blind clinical trial was
conducted on 80 women candidates for elective cesarean
section, under spinal anesthesia, who were admitted to
Bentolhoda Obstetrics and Gynecology Hospital in Bushehr,
Iran. Written informed consent was obtained from all
patients after full explanation of the procedure, and the study
was approved by the institutional Ethical Review Board.
The inclusion criterion was first pregnancy after
18 years of age.
Exclusion criteria were positive history of cardiovas-
cular disease, positive history of preeclampsia, allergy to
ergot alkaloids, uterine atony lasting more than five min-
utes, general anesthesia, chronic hypertension, emergent
cesarean section, and factors increasing the risk of atony,
including prolonged labor, polyhydramnios, multiparity,
and large baby.
Patients were randomized into two groups using com-
puter-generated randomizing schedules. While the patients
were entering the operation room, an intravenous line was
fixed, and 500 mL isotonic serum (0.9 % saline) was
administrated to each one. Baseline hemodynamic val-
ues—systolic blood pressure, diastolic blood pressure,
heart rate, and mean arterial blood pressure measured by
non-invasive blood pressure (NIBP) apparatus—were
recorded, using a checklist.
A single dose of intravenous metoclopramide (10 mg)
was administrated to all the patients three minutes before
spinal anesthesia.
Spinal anesthesia was performed on all the patients
while in a sitting position, using 12 mg hyperbaric intra-
arachnoidal procainamide 0.5 % (Milan, Italy) and 25
microgram fentanyl (Aburaihan Pharmaceutical Co.,
Tehran, Iran) via 25–26 gauge Barter spinal needle (Dr.
Japan Co., Japan) in the subarachnoid space between the
L3–L4 or L4–L5 vertebrae.
In the 1st, 3rd, and 5th min after spinal anesthesia, the
patients were monitored while in a supine position by
NIBP apparatus, and systolic and diastolic blood pressure,
heart rate, and mean arterial pressure were recorded.
If the systolic blood pressure decreased less than
90 mmHg, 10 mg intravenous ephedrine was injected as a
vasoconstrictor agent.
When the level of anesthesia reached T6, the Cesarean
section was initiated.
Thirty minutes after delivery, 0.2 mg methylergonovine
(Minoo Co, Tehran, Iran) in 1 L isotonic serum in the case
group, and 30 units oxytocin (Caspiantamin Pharmaceuti-
cal Co, Tehran, Iran) in 1 L isotonic serum in the control
group, were infused by an anesthesiologist. After drug
administration, systolic and diastolic blood pressure, heart
rate, and mean arterial pressure were recorded on the
checklist at 1, 3, 5, 10, 15, and 20 min, and every 5 min
until the end of the operation.
After surgery, all patients were transferred to a recovery
room. Primary outcome included amount of bleeding, which
was estimated by the amount in the field of surgery and the
amount of aspirated blood after suctioning amniotic fluids
into the bottle of a suction apparatus separately. Secondary
outcomes were systolic and diastolic blood pressure, heart
rate, and mean arterial pressure, which were recorded on the
checklist while entering the recovery room and at 5, 10, 15,
20, and 30 min. Incidence of dizziness, nausea, vomiting,
and the need for ephedrine as a vasoconstrictor were recor-
ded during the surgery and in the recovery room.
In order to detect differences with a 5 % level of sig-
nificance, 90 % power and a standard difference 1.0 sam-
ple size calculation estimated 80 patients by using the
Altman curve (http://ccforum.com/content/6/4/335).
Statistical analysis
Statistical analysis was performed with SPSS software
(version 16). Due to the non-parametric distribution of
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data, statistical significance for the differences was tested
by Chi-square for comparing frequencies, and Mann–
Whitney and the Kruskal–Wallis test for comparing mean
of variables, when appropriate. A p value less than 0.05
was considered statistically significant.
Results
Eighty patients met the inclusion criteria and were ran-
domly assigned to two groups. The 40 patients in the case
group received methylergonovine, and the 40 patients in
the control group received oxytocin.
No differences were found between the groups in terms
of mean age or baseline hemodynamic values, including
systolic and diastolic blood pressure, heart rate, and mean
arterial pressure (Table 1).
In addition, no differences were found between the
groups in terms of systolic and diastolic blood pressure,
heart rate, and mean arterial pressure after spinal anesthesia
at 1, 3, and 5 min (p [ 0.05).
After drug injection (oxytocin or methylergonovine),
statistically significant differences were found between the
two groups in terms of systolic and diastolic blood pres-
sure, heart rate, and mean arterial pressure. Heart rate in the
oxytocin group was statistically higher at 1 and 5 min.
Mean arterial pressure in the oxytocin group was statisti-
cally lower in minutes 1, 3, 5, 10, and 15. Systolic blood
pressure at minutes 1, 10, 15, and 20, and diastolic blood
pressure at minutes 1, 3, and 20 were statistically higher in
the methylergonovine group (Table 2).
No statistical significance was discovered between the
two groups in terms of systolic blood pressure, heart rate,
or mean arterial pressure during recovery (p [ 0.05); only
diastolic blood pressure was statistically higher in the
methylergonovine group in minute 20 in the recovery room
(p = 0.03).
As shown in Table 3, women in the methylergonovine
group had a significantly lower need for ephedrine as a
vasoconstrictor drug (p \ 0.0001).
No differences were observed between the groups in
terms of bleeding amount, nausea and vomiting, dizziness,
or time of atony during the operation and in recovery
(Table 3).
Discussion
The cardiovascular effects of oxytocin in animal models
and women undergoing Caesarean section include tachy-
cardia, hypotension, and decreased cardiac output. These
factors can be sufficient to cause significant compromise in
high-risk patients.
This study demonstrated that the need for ephedrine as a
vasoconstrictor drug in the methylergonovine group was
Table 1 Comparison of mean age and baseline hemodynamic values






Mean (SD) Mean (SD)
Mean age
(years)
27.45 ± 4.81 28.08 ± 5.13 0.06
SBP (mmHg) 130.83 (18.21) 128.60 (12.66) 0.54
DBP (mmHg) 83.51 (10.46) 83.76 (14.33) 0.93
HR (beat/min) 101.92 (19.21) 101.92 (19.21) 0.35
MAP (mmHg) 94.77 (15.30) 95.68 (14.94) 0.80
SBP systolic blood pressure, DBP diastolic blood pressure, HR heart
rate, MAP mean arterial pressure
* Statistical test: Mann–Whitney
Table 2 Comparison mean of hemodynamic values in minutes after
oxytocin and methylergonovine injection between the two groups
(n = 40)
Parameter Oxytocin group Methylergonovin p value*
Mean (SD) Mean (SD)
HR1 (b/m) 103.60 (15.5) 95.38 (15.04) 0.01
HR3 (b/m) 100.85 (15.12) 95.90 (18.69) 0.19
HR5 (b/m) 102.60 (15.64) 94.76 (17.65) 0.04
HR10 (b/m) 102.18 (13.80) 97.07 (13.93) 0.10
HR15 (b/m) 99.00 (12.51) 97.13 (14.60) 0.53
HR20 (b/m) 95.24 (13.12) 93.49 (14.09) 0.57
SBP1 (mmHg) 112.05 (12.98) 120.85 (20.56) 0.03
SBP3 (mmHg) 110.90 (14.47) 114.17 (13.76) 0.30
SBP5 (mmHg) 108.93 (12.58) 110.90 (11.67) 0.46
SBP10 (mmHg) 106.85 (12.83) 115.75 (16.27) 0.00
SBP15 (mmHg) 108.43 (12.48) 114.75 (10.87) 0.01
SBP20 (mmHg) 111.79 (12.69) 118.15 (12.40) 0.02
DBP1 (mmHg) 63.12 (12.19) 69.72 (12.39) 0.01
DBP3 (mmHg) 60.30 (12.14) 60.87 (10.31) 0.30
DBP5 (mmHg) 58.35 (11.60) 62.10 (10.80) 0.13
DBP10 (mmHg) 55.59 (12.47) 75.35 (7.48) 0.12
DBP15 (mmHg) 58.35 (12.36) 62.15 (8.03) 0.10
DBP20 (mmHg) 61.92 (11.69) 68.85 (12.14) 0.01
MAP1 (mmHg) 75.72 (12.08) 85.84 (12.13) 0.00
MAP3 (mmHg) 75.26 (13.11) 81.59 (9.87) 0.01
MAP5 (mmHg) 73.95 (12.22) 78.79 (10.02) 0.05
MAP10 (mmHg) 70.95 (11.44) 79.92 (13.22) 0.00
MAP15 (mmHg) 72.33 (10.75) 79.69 (12.65) 0.00
MAP20 (mmHg) 93.77 (10.29) 84.76 (12.29) 0.58
b/m beat/minute, SBP systolic blood pressure, DBP diastolic blood
pressure, HR heart rate, MAP mean arterial pressure
* Statistical test: Mann–Whitney
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significantly less than in the oxytocin group. No differences
were found between the two groups in terms of nausea,
vomiting, and dizziness.
Clinical outcomes in a study by Fujimoto et al. [10]
revealed that intramuscular administration of oxytocin,
compared with methylergometrine, was associated with a
significant reduction in postpartum blood loss and in fre-
quency of blood loss of more than 500 mL.
Another study, by Saito et al. [11], demonstrated that the
routine use of intramuscular oxytocin was more effective
than the use of intramuscular ergometrine for prevention of
postpartum hemorrhage in the third stage of labor. There
were no differences between the groups in terms of mean
duration of the third stage, mean level of hemoglobin on
the second postpartum day, frequency of postpartum
hemorrhage (C1,000 mL), or manual removal of placenta.
Fewer side effects were found, with no significant differ-
ences between the groups [11].
The results of our study differed from the Fujimoto and
Saito investigations. In our study, there were no differences
between the groups in terms of bleeding during the oper-
ation. This difference could be due to a difference in the
type of delivery and dosage of the drug administered. In
addition, in our study, methylergonovine and oxytocin
were infused intravenously, which was the novelty of our
study.
In a study by Kikutani et al. [12], the amount of blood
loss in the oxytocin groups were significantly lower than in
the methylergonovine group during Caesarean section
under spinal anesthesia. In our study, there was no
significant difference in amount of blood loss between the
groups.
However, in a study by Howard et al. [13], which was
conducted to assess the effects of oxytocin, methylerg-
onovine maleate, and a placebo, upon the fourth stage of
labor, methylergonovine maleate was the agent most
effective in preventing postpartum hemorrhage.
In a study by Svanstro¨m et al. [14], which was con-
ducted to compare oxytocin and methylergometrine during
Caesarean section under spinal anesthesia, oxytocin
administered as an intravenous bolus of 10 IU induced
chest pain, transient profound tachycardia, hypotension,
and concomitant signs of myocardial ischemia according to
marked ECG changes, while methylergometrine produced
mild hypertension and no significant ECG changes. This
study confirms the results of our study, in which tachy-
cardia and decreased mean arterial pressure after oxytocin
administration was observed.
In a study by Singh et al. [15], which was conducted to
compare sublingual misoprostol, intravenous oxytocin, and
intravenous methylergometrine in active management of
the third stage of labor, increased blood pressure was
observed significantly in the methylergometrine group in
comparison with the other groups.
In our study, after infusion of oxytocin and methy-
lergonovine during surgery, systolic blood pressure in the
methylergonovine group in minutes 1, 10, 15, and 20,
and diastolic blood pressure in minutes 1, 3, and 20,
were statistically higher than in the oxytocin group.
These hemodynamic changes in the methylergonovine
group demonstrate the relative stability of the hemody-
namic parameters in this group at those times.
There were two limitations to our study. The first limi-
tation was patients’ refusal for spinal anesthesia, as it is an
absolute contraindication for spinal anesthesia, and the
second was the limitation to selected primipara patients
who were candidates for elective Caesarean section.
This pilot study was designed to assess the effects of
methylergonovine in Caesarean section. Another, larger
clinical trial is required to determine the influence of
methylergonovine in Caesarean section.
In conclusion, our findings demonstrate that intravenous
infusion of methylergonovine can be applied instead of
intravenous oxytocin in elective Caesarean section under
spinal anesthesia, because it induces more hemodynamic
stability, prevents hypotension, and decreases the need for
vasoconstrictor drugs due to hypotension. In addition, the
side effects are not statistically different from those asso-
ciated with oxytocin.
Conflict of interest None.
Table 3 comparison of complications between the two groups
Parameter Oxytocin group Methylergonovin
group
p value




57.5 % 20 % \0.0001*
Bleeding while
operation (mL)
452.25 ± 120.18 433.25 ± 108.44 0.46**
N/V while
operation
32.5 % 22.5 % 0.32
N/V in recovery 5 % 7.5 % 0.65
Dizziness 2.5 % 2.5 % [0.05
Time of atony
(min)
4.13 ± 3.11 3.87 ± 2.41 0.81
N/V Nausea and vomiting, min minute
* Chi-square
** Mann–Whitney
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